Exercise News and Research

Latest Exercise News and Research

Phase 2 trial data of PET myocardial perfusion imaging with flurpiridaz F 18 presented at ICNC10

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced data from a Phase 2 clinical trial that demonstrated Positron Emission Tomography myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography myocardial perfusion imaging, the current standard for the non-invasive detection of CAD.

17 May 2011

High IGF-I hormone levels linked with better long-term recovery after stroke

Insulin-like growth factor I, IGF-I, is a hormone that is found in the blood and contributes to, among other things, growth and bone mass. The levels of this hormone are higher in people who exercise regularly and those with good health. Scientists at the Sahlgrenska Academy have shown for the first time that high levels of this hormone are associated with better long-term recovery after a stroke.

17 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

HealthPartners prescribes walking or exercise for patients with depression

Giving pedometers to patients screened for depression, HealthPartners Medical Group (HPMG) is prescribing walking or exercise in addition to medication and/or therapy as an effective tool in helping patients with depression.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

Wii Fit offers effective workout for patients with chronic obstructive pulmonary disease

According to a new study conducted by researchers in Connecticut, the Wii Fit- offers patients with chronic obstructive pulmonary disease an effective workout - and one that, because it is enjoyable, patients are more likely to use.

17 May 2011

Life expectancy blood test not popular with experts

According to scientists and medical ethicist there are hidden dangers of a new blood test for determining how fast someone is ageing. The test costs £435 test and is due to go on sale to the general public in Britain later this year, measures the length of a person's telomeres, the structures on the tips of the chromosomes which get progressively shorter with age. Short telomeres are linked with age-related diseases and premature death.

17 May 2011

Monarch completes Inspire cash tender offer at $5.00 per share

Merck, known as MSD outside the United States and Canada, announced today that Monarch Transaction Corp., its wholly-owned subsidiary, successfully completed the cash tender offer for all of the outstanding shares of common stock of Inspire Pharmaceuticals, Inc., which expired at 12:00 midnight, New York City time, on Thursday, May 12, 2011.

16 May 2011

Six-minute walking distance test effectively determines disease severity in COPD

The six-minute walking distance test, a test that measures a patient's ability to tolerate exercise and physical activity, is an effective tool for understanding disease severity in patients with chronic obstructive pulmonary disease, according to a three-year global study of patients with COPD sponsored by drug manufacturer GlaxoSmithKline.

16 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Study reveals role of KLF14 regulatory gene in type 2 diabetes

A team of researchers, led by King's College London and the University of Oxford, have found that a gene linked to type 2 diabetes and cholesterol levels is in fact a 'master regulator' gene, which controls the behaviour of other genes found within fat in the body.

16 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Vitamin D supplements may help patients with chronic obstructive pulmonary disease (COPD) get more from their pulmonary rehabilitation programs, according to a study conducted by researchers from Belgium.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Biodel enters deal with Great Point Partners, Orbimed Advisors to sell 12.2 million shares of common stock

Biodel Inc. today announced that it has entered into definitive agreements with a group of institutional investors, including Great Point Partners, LLC and Orbimed Advisors, LLC, to sell approximately 12.2 million shares of its common stock, 1.7 million shares of its Series A Convertible Preferred Stock and warrants to purchase 9.0 million shares of its common stock.

13 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

Spouse caregivers may have high risk of cognitive impairment or dementia

An older individual who cares for a spouse with dementia may be at an increased risk of developing cognitive problems because of the lifestyle that was shared with the spouse and because of the stress of caring for a loved one who is ill.

13 May 2011

Cipher first quarter net revenue decreases to $0.7 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2011.

12 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011